GC Cell Appoints Dr. Kim Ho-won as Chief Technology Officer

[Asia Economy Reporter Myunghwan Lee] GC Cell announced on the 9th that it has recruited Ho-won Kim, former CSO (Chief Scientific Officer) of K2B Therapeutics, as its new Chief Technology Officer (CTO).

New CTO Ho-won Kim graduated from Seoul National University College of Pharmacy, completed his master's degree at the same university, and earned a Ph.D. in Biochemistry from UCLA School of Medicine. He subsequently led cell therapy research at global biotech companies such as Stemgent, Origin, and Stemcell Technology.

Until recently, CTO Kim was the co-founder and Chief Scientific Officer (CSO) of K2B Therapeutics, a biotech company based in Boston, USA, where he led the development of anticancer drugs.

A GC Cell official stated, "New CTO Kim has extensive experience in the development and planning of cell therapies, including messenger RNA (mRNA) cell reprogramming, cell differentiation, and pluripotent stem cells," adding, "We expect him to set a new milestone in research and development (R&D) to strengthen the competitiveness of immune cell therapies such as NK and T cells."

This content was produced with the assistance of AI translation services.